ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics completed enrollment in the LOTIS-7 Phase 1b trial evaluating ZYNLONTA plus glofitamab in relapsed or refractory diffuse large B-cell lymphoma. The study treated 100 patients at a 150 µg/kg dose, with preliminary data showing an 89.8% overall response rate and 77.6% complete response rate in 49 evaluable patients.
Key figures
- Cr
- 77.6%
- Orr
- 89.8%
- Dose
- 150 µg/kg
- Sites total
- 30
- Pct relapsed
- 46%
- Patient pct eu
- 30%
- Patient pct us
- 70%
- Pct refractory
- 54%
- Follow up months
- 6
- Median age years
- 66
- Patients enrolled
- 100
- Efficacy evaluable patients
- 49
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.